Citicoline
Citicoline (CDP-Choline / Cognizin) · also known as CDP-choline, Cognizin, Citicoline
Oral citicoline can supply choline, and human studies show higher plasma choline and uridine. Animal studies suggest it can affect brain phospholipid synthesis and dopamine-related markers, but these effects have not been confirmed in humans.
Clinical uses and human evidence
Attention and focus
Age-related cognitive decline
Macular and vision protection
Studies (2)
- Lanza 2019 · Front Pharmacol · RCT · n=60 — Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
- Anton 2022 · Life (Basel) · RCT · n=73 — The Effect of Oral Citicoline and Docosahexaenoic Acid on the Visual Field of Patients with Glaucoma: A Randomized Trial
Mechanisms of action
Cholinergic neurotransmission (ACh precursor supply and AChE inhibition)
Citicoline provides choline, which can serve as a raw material for acetylcholine and phospholipid synthesis. However, how much is actually used depends on physiological state, and choline supply is not necessarily the rate-limiting step. Human studies measured higher plasma choline, and signals from choline-containing compounds in the brain also changed. This is not enough to confirm that acetylcholine synthesis or release in the brain clearly increases at usual doses.
Monoamine neurotransmitter balance (dopamine, norepinephrine, 5-HT)
In animal studies, rats given 300 mg/kg by intraperitoneal injection had higher striatal dopamine content, and striatal tyrosine hydroxylase activity also changed. This suggests dopamine metabolism may shift. These results come from animals, and the dose and route differ from usual oral dosing. There is still no reliable target validation in humans.
Neurotrophic factor synthesis and TrkB/A receptor activation
In rats with nerve injury, a higher dose of citicoline given by intraperitoneal injection raised BDNF gene expression in the trigeminal ganglion on day 3. This is an animal result at a high dose, so it cannot be assumed that usual oral dosing has the same effect in the human brain. Changes in synaptophysin also do not represent the BDNF or NGF pathway.